“The ability to control the delivery of a drug to a targeted depth is a significant development. The ability to deliver a
drug to a designated depth can both increase the efficacy of a drug, as well as possibly enable a decrease in the
amount of ‘drug’ needed to achieve the required therapeutic or prophylactic outcome.
While the technology was primarily developed as part of the ‘Needle-free Injection’ project, the patent may have
wider applications.”
And from a previous announcement
“Finally, commercial negotiations are at an advanced stage in respect of the further development, deployment and distribution of the KarmelSonix product range, including the WIM-PC and other products currently under development. A further announcement in respect of these negotiations is expected in the near term.”
- Forums
- ASX - By Stock
- NAL
- contract deal...will set it 40c
contract deal...will set it 40c, page-4
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some